SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

SpyGlass Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.00001 per share

(Title of Class of Securities)

(CUSIP Number)

Steven Schwen
3601 W. 76th Street, Suite 20
Edina, MN, 55435
612-217-8680

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

11/16/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Vensana Capital I GP, LLC
2	Check the appropriate box if a member of a Group (See Instructions)

	☐ (a) ☑ (b)	
3	SEC use only	
4	Source of funds (See Instructions) AF	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 12.00
	8	Shared Voting Power 2,979,583.00
	9	Sole Dispositive Power 12.00
	10	Shared Dispositive Power 2,979,583.00
11	Aggregate amount beneficially owned by each reporting person 2,979,595.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 8.9 %	
14	Type of Reporting Person (See Instructions) OO	

Comment for Type of Reporting Person: All shares reported in Rows 7 and 9 are held of record by Vensana GP I. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. All shares reported in Rows 8 and 10 are held of record by Vensana I (as defined in Item 2(a) of the Original Schedule 13D (as defined below)). Vensana GP I (as defined in Item 2(a) of the Original Schedule 13D) is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock (as defined in Item 1 of the Original Schedule 13D) outstanding as of November 2, 2026, as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission (the "Commission") on November 12, 2026 (the Form "10-Q").

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Vensana Capital I, L.P.	
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)	

3	SEC use only	
4	Source of funds (See Instructions) WC	
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐	
6	Citizenship or place of organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	7 Sole Voting Power 0.00	
	8 Shared Voting Power 2,979,583.00	
	9 Sole Dispositive Power 0.00	
	10 Shared Dispositive Power 2,979,583.00	
11	Aggregate amount beneficially owned by each reporting person 2,979,583.00	
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐	
13	Percent of class represented by amount in Row (11) 8.9 %	
14	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: All such shares are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.

SCHEDULE 13D

CUSIP No.

1	Name of reporting person Kirk Nielsen
2	Check the appropriate box if a member of a Group (See Instructions) ☐ (a) ☑ (b)
3	SEC use only
4	Source of funds (See Instructions) AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e) ☐
6	Citizenship or place of organization

	UNITED STATES	
Number of Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 10,038.00
	8	Shared Voting Power 2,979,583.00
	9	Sole Dispositive Power 10,038.00
	10	Shared Dispositive Power 2,979,583.00
	11	Aggregate amount beneficially owned by each reporting person 2,989,621.00
	12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
	13	Percent of class represented by amount in Row (11) 8.9 %
	14	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: The shares reported in Rows 7 and 9 consist of (i) 8,372 shares subject to stock options granted to Kirk Nielsen in his capacity as a director of the Issuer that are exercisable as of the date of filing this Amendment (as defined in Item 1 below) or within 60 days thereafter, (ii) 796 shares held of record by the Kirk G. Nielsen Revocable Trust, and (iii) 870 shares held of record by the H17 Trust. Kirk Nielsen is the trustee of the Kirk G. Nielsen Revocable Trust and the Investment Trust Advisor of the H17 Trust and may be deemed to share voting, investment and dispositive power with respect to the securities held by each of the Kirk G. Nielsen Revocable Trust and the H17 Trust. The shares reported in Rows 8 and 10 are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.

SCHEDULE 13D

CUSIP No.

	Name of reporting person	
1		Peter Justin Klein
	Check the appropriate box if a member of a Group (See Instructions)	
2		☐ (a) ☑ (b)
3	SEC use only	
	Source of funds (See Instructions)	
4		AF
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)	
5		☐
	Citizenship or place of organization	
6		UNITED STATES
Number of		

Shares Beneficially Owned by Each Reporting Person With:	7	Sole Voting Power 1,666.00
	8	Shared Voting Power 2,979,583.00
	9	Sole Dispositive Power 1,666.00
	10	Shared Dispositive Power 2,979,583.00
11		Aggregate amount beneficially owned by each reporting person 2,981,249.00
12		Check if the aggregate amount in Row (11) excludes certain shares (See Instructions) ☐
13		Percent of class represented by amount in Row (11) 8.9 %
14		Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: The shares reported in Rows 7 and 9 are held of record by Peter Justin Klein directly. The shares reported in Rows 8 and 10 are held of record by Vensana I. Vensana GP I is the general partner of Vensana I and may be deemed to have voting, investment and dispositive power with respect to these securities. Kirk Nielsen, a member of the Issuer's board of directors, and Peter Justin Klein are the managing directors of Vensana GP I and may each be deemed to share voting, investment and dispositive power with respect to these securities. The percentage in Row 13 is based on 33,461,450 shares of Common Stock outstanding as of November 2, 2026, as set forth in the Form 10-Q.

SCHEDULE 13D

Item 1. Security and Issuer

(a) Title of Class of Securities:

Common Stock, par value $0.00001 per share

(b) Name of Issuer:

SpyGlass Pharma, Inc.

(c) Address of Issuer's Principal Executive Offices:

15326 Alton Parkway, Irvine, CALIFORNIA , 92618.

Item 1 Comment: This Amendment No. 1 (this "Amendment") amends and supplements the Schedule 13D originally filed by the Reporting Persons with the Commission on February 10, 2026 (the "Original Schedule 13D"). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.

Item 4. Purpose of Transaction

Solely on behalf of, and only to the extent that it relates to, the Reporting Persons, Item 4 of the Original Schedule 13D is hereby amended and supplemented by the addition of the following: The Reporting Persons have previously reserved the right and continue to reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional shares of Common Stock or other securities of the Issuer, dispose of some or all of the shares of Common Stock or other securities of the Issuer that it may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing. The Reporting Persons intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer's business, financial condition, results of operations and prospects, general

economic and industry conditions, the securities markets in general and those for the Issuer's stock in particular, as well as other developments.

Item 5. Interest in Securities of the Issuer

(a) See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person.

(b) See Items 7-11 and 13 of the cover pages of this Statement for each Reporting Person.

(c) On November 16, 2026, Vensana I effected a pro rata distribution without additional consideration of 331,036 shares of Common Stock to (i) Vensana GP I and (ii) its limited partners. Vensana GP I then effected a pro rata distribution without additional consideration of 8,634 shares of Common Stock that it received in connection with such distribution to its members.

(e) Not Applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Vensana Capital I GP, LLC

Signature: /s/ Steven Schwen
Name/Title: Steven Schwen, Chief Financial Officer
Date: 11/18/2026

Vensana Capital I, L.P.

Signature: /s/ Steven Schwen
Name/Title: Steven Schwen, Chief Financial Officer of Vensana Capital I GP, LLC, the general partner of Vensana Capital I, L.P.
Date: 11/18/2026

Kirk Nielsen

Signature: /s/ Steven Schwen
Name/Title: Attorney-in-Fact*
Date: 11/18/2026

Peter Justin Klein

Signature: /s/ Steven Schwen
Name/Title: Attorney-in-Fact*
Date: 11/18/2026

Comments accompanying signature: *This Amendment was executed pursuant to a Power of Attorney. Note that copies of all applicable Powers of Attorney are already on file with the appropriate agencies.